
Cryo-Cell International, Inc.: updates and filings
Price
$4.48
November 16, 2026Market cap $36M
What Ploutos Investor adds for Cryo-Cell International
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
September 2026
November 2025
October 2025
September 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Oct 28, 2026Shareholder voteForm8-K
- Oct 13, 2026Annual meeting proxy statementFormDEF 14A
- Oct 13, 2026Annual report to shareholdersfor the period to Nov 30, 2025FormARS
- Oct 9, 2026Quarterly reportfor the period to Aug 31, 2026Form10-Q
- Sep 14, 2026Other material eventsForm8-K
- Jul 15, 2026Quarterly reportfor the period to May 31, 2026Form10-Q
- Jul 7, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 8, 2026Delisting notice, Regulation FD disclosureForm8-K
- Apr 14, 2026Quarterly reportfor the period to Feb 28, 2026Form10-Q
- Mar 25, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Mar 12, 2026Delisting notice, Regulation FD disclosureForm8-K
- Feb 27, 2026Annual reportfor the period to Nov 30, 2025Form10-K
- Nov 12, 2025Other material eventsForm8-K
- Oct 23, 2025Material agreement entered, new material financial obligationForm8-K
- Oct 15, 2025Quarterly reportfor the period to Aug 31, 2025Form10-Q
- Sep 26, 2025Annual meeting proxy statementFormDEF 14A
- Sep 26, 2025Annual report to shareholdersfor the period to Nov 30, 2024FormARS
- Sep 10, 2025Other material eventsForm8-K
- Jul 15, 2025Quarterly reportfor the period to May 31, 2025Form10-Q
- May 22, 2025Material agreement endedForm8-K
- May 8, 2025Other material eventsForm8-K
- Apr 14, 2025Quarterly reportfor the period to Feb 28, 2025Form10-Q
- Feb 28, 2025Annual reportfor the period to Nov 30, 2024Form10-K
- Dec 27, 2024Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 12, 2024Shares registered for employeesFormS-8
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Oct 28, 2026 | 8-K | Shareholder vote | Document |
| Oct 13, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Oct 13, 2026 | ARS | Annual report to shareholdersfor the period to Nov 30, 2025 | Document |
| Oct 9, 2026 | 10-Q | Quarterly reportfor the period to Aug 31, 2026 | Document |
| Sep 14, 2026 | 8-K | Other material events | Document |
| Jul 15, 2026 | 10-Q | Quarterly reportfor the period to May 31, 2026 | Document |
| Jul 7, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 8, 2026 | 8-K | Delisting notice, Regulation FD disclosure | Document |
| Apr 14, 2026 | 10-Q | Quarterly reportfor the period to Feb 28, 2026 | Document |
| Mar 25, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Mar 12, 2026 | 8-K | Delisting notice, Regulation FD disclosure | Document |
| Feb 27, 2026 | 10-K | Annual reportfor the period to Nov 30, 2025 | Document |
| Nov 12, 2025 | 8-K | Other material events | Document |
| Oct 23, 2025 | 8-K | Material agreement entered, new material financial obligation | Document |
| Oct 15, 2025 | 10-Q | Quarterly reportfor the period to Aug 31, 2025 | Document |
| Sep 26, 2025 | DEF 14A | Annual meeting proxy statement | Document |
| Sep 26, 2025 | ARS | Annual report to shareholdersfor the period to Nov 30, 2024 | Document |
| Sep 10, 2025 | 8-K | Other material events | Document |
| Jul 15, 2025 | 10-Q | Quarterly reportfor the period to May 31, 2025 | Document |
| May 22, 2025 | 8-K | Material agreement ended | Document |
| May 8, 2025 | 8-K | Other material events | Document |
| Apr 14, 2025 | 10-Q | Quarterly reportfor the period to Feb 28, 2025 | Document |
| Feb 28, 2025 | 10-K | Annual reportfor the period to Nov 30, 2024 | Document |
| Dec 27, 2024 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 12, 2024 | S-8 | Shares registered for employees | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 28, 1997.
The full analysis
What do Cryo-Cell International's filings show?
The filings are where every one of Cryo-Cell International's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.